Eva I. Montero
Autonomous University of Madrid
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Eva I. Montero.
Journal of Inorganic Biochemistry | 1998
Adoración G. Quiroga; José M. Pérez; Eva I. Montero; José R. Masaguer; Carlos Alonso; Carmen Navarro-Ranninger
In the present paper we report the synthesis and characterization by 1H 13C NMR and heteronuclear 2D NMR spectroscopies of two new metallic complexes derived from phenylacetaldehyde thiosemincarbazone: Pt(C9H11N3S)Cl2, compound 2, and Pd(C9H11N3S)Cl2, compound 3. The testing of the cytotoxic activity of these compounds against several human and murine cell lines sensitive and resistant to cis-DDP suggests that compounds 2 and 3 may be considered potential anticancer agents since they exhibit 1C50 values in a microM range similar to cisplatin (cis-DDP). The cytotoxic activity of these compounds is higher in cis-DDP-resistant tumor cells than that of other antitumor drugs such as etoposide and adriamycin. On the other hand, the analysis of the interaction of compounds 2 and 3 with linear plasmid DNA indicate that both compounds, particularly compound 3, have an enhanced capacity to form DNA interstrand cross-links in comparison with cis-DDP.
Journal of Inorganic Biochemistry | 1999
Adoración G. Quiroga; José M. Pérez; Eva I. Montero; Douglas X. West; Carlos Alonso; Carmen Navarro-Ranninger
Cytotoxicity tests in tumor cells sensitive to cis-DDP (HL-60, JURKAT, Hela and 3T3) and in tumor cells transformed by ras oncogenes and resistant to cis-DDP (Pam 212-ras) show that cyclometallated complexes 1a [Pd(p-is.TSCN-NHMe)]4, 2b [Pt(p-is.TSCN-NMe2)]4 and 4a [Pd(p-is.TSCN-NHex)]4 may be endowed with specific cytotoxic properties. In fact, these three novel metal-thiosemicarbazone compounds kill Pam 212-ras cells through apoptosis induction. These results, together with others recently published, indicate that the design and synthesis of metallated-thiosemicarbazone compounds may lead to the discovery of novel antitumor agents able to circumvent cis-DDP resistance, in particular tumor cell lines.
Journal of Inorganic Biochemistry | 1998
Adoración G. Quiroga; José M. Pérez; Isabel López-Solera; Eva I. Montero; José R. Masaguer; Carlos Alonso; Carmen Navarro-Ranninger
Two novel dimeric chloro-bridged complexes [Pd (p-is. TSCN) (mu-Cl)]2, 2, and [Pt (p-is. TSCN)(mu-Cl)]2, 3, where p-is. TSCN = p-isopropylbenzaldehyde thiosemicarbazone, 1, have been synthesized and characterized by IR and NMR spectroscopy. The in vitro antitumor activity shown by both compounds against several human and murine cell lines sensitive and resistant to the clinically-used drug cisplatin (cis-DDP) suggests that compounds 2 and 3 may be endowed with important anticancer properties. Thus, compounds 2 and 3 not only show IC50 values in the microM range as cis-DDP but also display cytotoxic activity in tumor cell lines resistant to this drug. The analysis of the interaction of these binuclear p-is. TSCN compounds with DNA secondary and tertiary structures indicate that they form DNA interhelical cross-links, a biochemical property that may be involved in their mechanism of action.
ChemBioChem | 2002
Eva I. Montero; José M. Pérez; Annie Schwartz; Miguel A. Fuertes; Jean Marc Malinge; Carlos Alonso; Marc Leng; Carmen Navarro-Ranninger
We have investigated the cytotoxic activity, the induction of apoptosis, and the interstrand cross‐linking efficiency in the A2780cisR ovarian tumor cell line, after replacement of the two NH3 nonleaving groups in trans‐[PtCl2(NH3)2] (trans‐DDP) by dimethylamine and isopropylamine. The data show that trans‐[PtCl2(NH(CH3)2)(NHCH(CH3)2)] is able to circumvent resistance to cis‐[PtCl2(NH3)2] (cis‐DDP, cisplatin) in A2780cisR cells. In fact, trans‐[PtCl2(NH(CH3)2)(NHCH(CH3)2)] shows a cytotoxic potency higher than that of cis‐DDP and trans‐DDP, with the mean IC50 values being 11, 58, and 300 μM, respectively. In addition, at equitoxic doses (concentrations of the platinum drugs equal to their IC50 values) and after 24 hours of drug treatment, the level of induction of apoptosis by trans‐[PtCl2(NH(CH3)2)(NHCH(CH3)2)] is twice that produced by cis‐DDP. Under the same experimental conditions, trans‐DDP does not induce significant levels of apoptosis in A2780cisR cells. After 24 hours of incubation of A2780cisR cells at concentrations equal to the IC50 value of the platinum drugs, the level of DNA interstrand cross‐links (ICLs) induced by trans‐[PtCl2(NH(CH3)2)(NHCH(CH3)2)] is two and three times higher, respectively, than those induced by cis‐DDP and trans‐DDP. We also found that trans‐[PtCl2(NH(CH3)2)(NHCH(CH3)2)] formed DNA ICLs between guanine and complementary cytosine. We propose that, in A2780cisR cells, the induction of apoptosis by trans‐[PtCl2(NH(CH3)2)(NHCH(CH3)2)] is related to its greater ability (relative to cis‐DDP and trans‐DDP) to form DNA ICLs.
Journal of Inorganic Biochemistry | 1999
José M. Pérez; Adoración G. Quiroga; Eva I. Montero; Carmen Herrero Alonso; Carmen Navarro-Ranninger
cis-Diamminedichloroplatinum(II) (cis-DDP) is a widely used antitumour drug which produces important damage on the DNA inducing apoptosis in several cell lines. We have analyzed the cytotoxic activity of novel cyclometallated complexes of p-isopropylbenzaldehyde thiosemicarbazone (p-is.TSCN) and their dimeric chloro-bridged derivatives in murine keratinocytes transformed by the H-ras oncogene which are resistant to cis-DDP (Pam-ras cells). The data show that, in contrast with cis-DDP, the tetrameric cycloplatinated complex [Pt(p-is.TSCN)]4 and its dimeric chloro-bridged derivative [Pt(microCl)(p-is.TSCN)]2 have a good in vitro therapeutic index when comparing the cytotoxicity in Pam-ras cells to normal murine keratinocytes (Pam 212 cells) since they induce cell death in Pam-ras cells at drug concentrations significantly lower than those needed to kill Pam 212 cells. At equitoxic doses (IC90), both complexes produce characteristic features of apoptosis in Pam-ras cells together with a drastic decrease in levels of H-ras protein. These effects are not observed when the cells are treated with the IC90 of the cis-DDP drug nor the p-is.TSCN ligand. Altogether, these results suggest that the platinum compounds [Pt(p-is.TSCN)]4 and [Pt(microCl)(p-is.TSCN)]2 might have potential as antitumour agents in view of their specific induction of apoptosis in cis-DDP resistant cells.
Metal-based Drugs | 2001
Jose M. Perez; Eva I. Montero; Adoración G. Quiroga; Miguel A. Fuertes; Carlos Alonso; Carmen Navarro-Ranninger
Trans-[PtCl2(N,N-dimethylamine)(isopropylamine)] is a novel trans-platinum compound that shows cytotoxic activity in several cisplatin resistant cell lines. The aim of this paper was to analyse, by means of molecular cell biology techniques and total reflection X-ray fluorescence (TXRF), the cytotoxic activity, the induction of apoptosis, the cellular uptake and the DNA binding of trans-[PtCl2(N,N-dimethylamine)(isopropylamine)] in the cisplatin resistant cell line A2780cisR. The results show that this drug is more cytotoxic and induces a higher amount of apoptotic cells than cisplatin in A2780cisR cells. However, the intracellular accumulation and extent of binding to DNA of trans-[PtCl2(N,N-dimethylamine)( isopropylamine)] is lower than that of cis-DDP. Moreover, trans-[PtCl2(N,N-dimethylamine)(isopropylaminae)] is partially inactivated by intracellular levels of glulathione. The result suggest that circumvention of ciplatin resistance by trans-[PtCl2(N,N-dimethylamine)(isopropylamine)] in A2780cisR cells might be related with the ability of this drug to induce apoptosis.
Journal of Organometallic Chemistry | 1998
Carmen Navarro-Ranninger; Eva I. Montero; Isabel López-Solera; José R. Masaguer; Bernhard Lippert
Abstract The acetate bridges in a cyclometallated, dinuclear complex 3 of Pd(II) with the 3,8-dinitro-6-phenylphenanthridine ligand can be substituted by the deprotonated model nucleobase 1-methylcytosine to give a doubly bridged 1-methylcytosinato complex 4 . 4 has a folded structure as concluded from 1 H NMR spectroscopy.
Journal of Medicinal Chemistry | 1999
Eva I. Montero; Sonia Díaz; Ana Ma González-Vadillo; Jose M. Perez; Carmen Herrero Alonso; Carmen Navarro-Ranninger
Molecular Pharmacology | 2003
Jose M. Perez; Lloyd R. Kelland; Eva I. Montero; Frances E. Boxall; Miguel A. Fuertes; Carlos Alonso; Carmen Navarro-Ranninger
Journal of Medicinal Chemistry | 1999
José M. Pérez; Isabel López-Solera; Eva I. Montero; Miguel F. Braña; Carlos Alonso; Simon P. Robinson; Carmen Navarro-Ranninger